{"id":14870,"date":"2026-06-03T06:00:00","date_gmt":"2026-06-03T10:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=14870"},"modified":"2026-05-22T12:48:33","modified_gmt":"2026-05-22T16:48:33","slug":"covid-19-and-nail-unit-pathology-fingernail-and-toenail-manifestations-mechanisms-and-clinical-significance","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=14870","title":{"rendered":"COVID-19 and Nail Unit Pathology: Fingernail and Toenail Manifestations, Mechanisms, and Clinical Significance"},"content":{"rendered":"\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Abstract <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19 is a multisystem infectious disease caused by SARS-CoV-2 with well-documented respiratory, cardiovascular, neurologic, and dermatologic manifestations. Increasing evidence indicates that the nail unit represents a delayed and visually accessible biomarker of systemic inflammatory, vascular, and metabolic disruption induced by acute infection. Reported abnormalities include Beau\u2019s lines, onychomadesis, transverse erythronychia, and dyschromia patterns affecting both fingernails and toenails. These changes likely reflect transient arrest of nail matrix proliferation secondary to cytokine-mediated inflammation, endothelial injury, hypoxic stress, and autonomic dysregulation. This review series synthesizes current evidence on pathophysiology, clinical morphology, temporal evolution, and post-acute sequelae of COVID-19\u2013associated nail disease.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">1. Introduction<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Since the emergence of SARS-CoV-2 in late 2019, COVID-19 has been recognized as a systemic disease extending beyond the respiratory tract. Dermatologic manifestations were among the earliest extra-pulmonary findings described, including urticarial eruptions, morbilliform rashes, chilblain-like lesions, and vascular purpura. Within this expanding clinical spectrum, nail unit abnormalities have emerged as a delayed but reproducible feature of systemic involvement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Unlike cutaneous eruptions that often coincide with acute infection, nail changes typically present weeks to months later, reflecting the slow growth rate of the nail apparatus. This delayed temporal relationship positions the nail unit as a \u201cbiological record\u201d of systemic physiologic stress during the period of infection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reports of transverse nail depressions (Beau\u2019s lines), nail shedding (onychomadesis), and dyschromia following COVID-19 infection have prompted renewed interest in nail biology as a diagnostic and prognostic window into systemic viral disease.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">2. Anatomy and Physiology of the Nail Unit<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The nail unit is composed of four integrated structures:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Nail matrix<\/strong> \u2013 responsible for nail plate production<\/li>\n\n\n\n<li><strong>Nail bed<\/strong> \u2013 supports the overlying nail plate<\/li>\n\n\n\n<li><strong>Nail plate<\/strong> \u2013 keratinized structure formed by matrix keratinocytes<\/li>\n\n\n\n<li><strong>Periungual tissue<\/strong> \u2013 vascular and epithelial support structures<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">The nail matrix is particularly metabolically active, with continuous keratinocyte proliferation driving longitudinal nail growth. Fingernails grow at an average rate of approximately 3 mm per month, while toenails grow at roughly 1 mm per month. This slow turnover means that any systemic insult affecting matrix function will manifest as a <strong>delayed structural defect<\/strong> in the nail plate.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The nail unit is highly sensitive to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>systemic inflammation<\/li>\n\n\n\n<li>febrile illness<\/li>\n\n\n\n<li>hypoxia<\/li>\n\n\n\n<li>vascular compromise<\/li>\n\n\n\n<li>nutritional deficiency<\/li>\n\n\n\n<li>neuroendocrine stress<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These same physiological domains are prominently affected in moderate-to-severe COVID-19, making nail pathology biologically plausible in this disease context.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">3. Biological Vulnerability of the Nail Matrix in Systemic Disease<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The nail matrix is particularly susceptible to systemic perturbation due to several features:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3.1 High proliferative demand<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Matrix keratinocytes divide continuously, requiring stable oxygenation and metabolic supply.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3.2 Terminal microvascular supply<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The nail matrix is supplied by fine terminal vessels with limited collateral circulation, making it vulnerable to ischemia during systemic endothelial dysfunction.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3.3 Cytokine sensitivity<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Inflammatory mediators such as IL-6, TNF-\u03b1, and IL-1\u03b2 can directly suppress keratinocyte proliferation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3.4 Lack of regenerative redundancy<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Unlike other epithelial tissues, the nail matrix lacks rapid compensatory regenerative mechanisms following injury.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Together, these properties render the nail unit a sensitive indicator of systemic physiologic disruption.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">4. Early Observations of Nail Changes in COVID-19<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Initial reports from dermatology and infectious disease cohorts identified nail abnormalities in patients recovering from SARS-CoV-2 infection. These findings were initially considered incidental but have since been recognized as part of a broader post-viral phenotype.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Common early-reported findings include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>transverse nail depressions consistent with Beau\u2019s lines<\/li>\n\n\n\n<li>complete temporary nail shedding (onychomadesis)<\/li>\n\n\n\n<li>changes in nail coloration (erythronychia, leukonychia)<\/li>\n\n\n\n<li>brittle or ridged nail plates<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, these changes often appeared <strong>4\u201312 weeks after acute infection<\/strong>, aligning with nail growth dynamics.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">5. Beau\u2019s Lines as a Systemic Stress Marker<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Beau\u2019s lines represent transverse grooves in the nail plate caused by temporary cessation of nail matrix activity. They are classically associated with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>severe febrile illness<\/li>\n\n\n\n<li>systemic inflammation<\/li>\n\n\n\n<li>chemotherapy exposure<\/li>\n\n\n\n<li>major physiologic stress events<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">In the context of COVID-19, Beau\u2019s lines likely reflect a combination of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>systemic cytokine surge<\/li>\n\n\n\n<li>hypoxic stress during acute infection<\/li>\n\n\n\n<li>endothelial dysfunction<\/li>\n\n\n\n<li>metabolic suppression of keratinocyte activity<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Because nail growth is slow and linear, Beau\u2019s lines function as a <strong>temporal marker of past systemic insult<\/strong>, effectively encoding the timing of disease severity.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">6. Onychomadesis and Severe Matrix Arrest<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Onychomadesis represents a more severe form of nail matrix dysfunction, characterized by complete cessation of nail production leading to proximal nail shedding.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In COVID-19\u2013associated cases, onychomadesis suggests:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>profound inflammatory or ischemic insult<\/li>\n\n\n\n<li>prolonged metabolic suppression<\/li>\n\n\n\n<li>possible immune-mediated epithelial injury<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Although less common than Beau\u2019s lines, its presence may indicate more severe systemic disease burden or prolonged inflammatory response.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">7. Emerging Hypothesis: COVID-19 as a Multidomain Nail Disease Trigger<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Based on early clinical observations, COVID-19 may affect the nail unit through a convergence of:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Inflammatory pathway activation<\/strong> (cytokine-mediated matrix suppression)<\/li>\n\n\n\n<li><strong>Vascular injury<\/strong> (endothelial dysfunction and microthrombosis)<\/li>\n\n\n\n<li><strong>Hypoxic stress<\/strong> (reduced oxygen delivery during acute infection)<\/li>\n\n\n\n<li><strong>Autonomic imbalance<\/strong> (post-viral dysregulation of peripheral perfusion)<\/li>\n\n\n\n<li><strong>Nutritional and metabolic disruption<\/strong> (systemic illness effects)<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">This multifactorial model explains the heterogeneity of nail findings across patients.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">8. Rationale for Further Study<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Despite growing recognition of COVID-19\u2013associated nail pathology, several gaps remain:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>lack of large longitudinal cohort studies<\/li>\n\n\n\n<li>limited histopathologic confirmation of nail matrix injury<\/li>\n\n\n\n<li>unclear correlation with disease severity tiers<\/li>\n\n\n\n<li>insufficient mechanistic studies linking cytokines to nail growth arrest<\/li>\n\n\n\n<li>underrepresentation of toenail pathology in literature<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Part II \u2014 Mechanisms of Nail Injury: Cytokine, Vascular, and Hypoxic Pathways<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">9. Cytokine-Mediated Suppression of Nail Matrix Activity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A central mechanism underlying COVID-19\u2013associated nail abnormalities is <strong>systemic inflammatory signaling<\/strong>, particularly involving IL-6, TNF-\u03b1, and IL-1\u03b2. These cytokines are markedly elevated in moderate-to-severe SARS-CoV-2 infection and are known to suppress keratinocyte proliferation and disrupt epithelial homeostasis.\u00b9<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The nail matrix, characterized by high proliferative turnover, is especially sensitive to inflammatory arrest. Experimental dermatologic models have demonstrated that IL-6 signaling inhibits keratinocyte cell-cycle progression via JAK\/STAT pathway modulation.\u00b2 TNF-\u03b1 further amplifies this effect by inducing apoptosis in rapidly dividing epithelial cells.\u00b3<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In COVID-19, this cytokine milieu creates a transient \u201cgrowth arrest window\u201d in the nail matrix, which later manifests as Beau\u2019s lines or onychomadesis once nail plate growth resumes.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">10. Endothelial Dysfunction and Microvascular Injury<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SARS-CoV-2 induces widespread endothelial injury via ACE2 receptor\u2013mediated infection and downstream inflammatory activation.\u2074 Endothelialitis and microthrombotic phenomena have been documented across multiple organ systems, including pulmonary, renal, and cutaneous vascular beds.\u2075<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The nail unit is supplied by terminal microvasculature with minimal collateral flow, rendering it highly vulnerable to ischemic injury. Nail matrix hypoperfusion results in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>temporary keratinocyte metabolic shutdown<\/li>\n\n\n\n<li>localized ischemia-reperfusion injury<\/li>\n\n\n\n<li>structural deformation of newly formed nail plate<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Histopathologic studies of COVID-19 skin biopsies have demonstrated complement-mediated microvascular injury, supporting a systemic vasculopathic process.\u2076<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This vascular hypothesis is strongly supported by the temporal delay between infection and nail manifestation, consistent with post-ischemic growth disturbances.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">11. Hypoxia-Induced Keratinocyte Dysfunction<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hypoxemia is a hallmark of moderate and severe COVID-19. Even in \u201csilent hypoxia,\u201d tissue oxygen delivery is compromised.\u2077 Nail matrix keratinocytes rely heavily on aerobic metabolism due to continuous proliferation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hypoxia induces:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ATP depletion<\/li>\n\n\n\n<li>mitochondrial dysfunction<\/li>\n\n\n\n<li>altered keratin synthesis<\/li>\n\n\n\n<li>cell-cycle arrest in G1 phase<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These effects collectively impair nail plate formation during acute infection, resulting in later-visible growth defects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hypoxia-inducible factor (HIF-1\u03b1) signaling may further modulate keratinocyte differentiation, contributing to abnormal nail plate architecture.\u2078<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">12. Combined Pathophysiologic Model of Nail Injury<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19\u2013associated nail pathology is best explained by a <strong>multifactorial convergence model<\/strong>:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">12.1 Inflammatory axis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>IL-6\u2013driven suppression of matrix proliferation<\/li>\n\n\n\n<li>TNF-\u03b1\u2013mediated apoptosis of keratinocytes<\/li>\n\n\n\n<li>IL-1\u03b2\u2013induced epithelial stress response<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">12.2 Vascular axis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>endothelial dysfunction<\/li>\n\n\n\n<li>microthrombi formation<\/li>\n\n\n\n<li>reduced perfusion of nail matrix capillaries<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">12.3 Hypoxic axis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>systemic oxygen deprivation<\/li>\n\n\n\n<li>mitochondrial dysfunction in proliferative keratinocytes<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">12.4 Neuroendocrine axis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>autonomic imbalance affecting peripheral circulation<\/li>\n\n\n\n<li>stress hormone elevation (cortisol-mediated growth suppression)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These pathways act synergistically rather than independently, producing a spectrum of nail abnormalities depending on severity and duration of systemic illness.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">13. Clinical Spectrum in Early COVID-19 Cohorts<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Observational dermatologic studies during the pandemic reported nail findings in recovered patients across multiple cohorts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a multicenter European dermatology registry, nail changes were documented in patients 3\u201312 weeks following infection, with Beau\u2019s lines being the most frequent manifestation.\u2079<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reported prevalence estimates vary widely (2\u201325%), reflecting:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>differences in disease severity<\/li>\n\n\n\n<li>underreporting of mild nail changes<\/li>\n\n\n\n<li>delayed presentation relative to acute illness<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Onychomadesis, while less common, has been consistently reported in patients with severe systemic involvement or prolonged hospitalization.\u00b9\u2070<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">14. Temporal Dynamics of Nail Manifestations<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A defining feature of COVID-19\u2013related nail pathology is its <strong>delayed onset relative to infection<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Because fingernails grow at approximately 3 mm\/month and toenails at ~1 mm\/month:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>proximal nail matrix injury appears weeks later as transverse bands<\/li>\n\n\n\n<li>toenail manifestations may lag by several months<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This creates a \u201cbiological lag signature\u201d of infection, allowing retrospective identification of systemic stress events.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">15. Differential Diagnosis of COVID-19\u2013Associated Nail Findings<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nail changes observed in COVID-19 must be differentiated from other systemic conditions:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">15.1 Febrile illnesses<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>influenza<\/li>\n\n\n\n<li>bacterial sepsis<\/li>\n\n\n\n<li>other viral infections<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">15.2 Drug-induced changes<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>chemotherapy (Beau\u2019s lines, onycholysis)<\/li>\n\n\n\n<li>retinoids (nail fragility)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">15.3 Nutritional deficiencies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>zinc deficiency<\/li>\n\n\n\n<li>protein-calorie malnutrition<\/li>\n\n\n\n<li>iron deficiency anemia<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">15.4 Dermatologic diseases<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>psoriasis<\/li>\n\n\n\n<li>lichen planus<\/li>\n\n\n\n<li>alopecia areata\u2013associated nail changes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The temporal association with SARS-CoV-2 infection is therefore critical for attribution.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">16. Pathophysiologic Integration<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The current evidence supports COVID-19 as a <strong>systemic nail matrix stressor<\/strong> operating through three primary mechanisms:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Inflammatory suppression of keratinocyte proliferation<\/strong><\/li>\n\n\n\n<li><strong>Endothelial and microvascular injury to nail matrix perfusion<\/strong><\/li>\n\n\n\n<li><strong>Hypoxia-induced metabolic arrest of nail production<\/strong><\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">These mechanisms converge to produce a delayed but highly characteristic pattern of nail growth disruption.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">17. Interim Summary<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19\u2013associated nail pathology reflects systemic disease severity rather than localized infection. The nail unit functions as a slow-growing record of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>inflammatory burden<\/li>\n\n\n\n<li>vascular compromise<\/li>\n\n\n\n<li>hypoxic stress<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Beau\u2019s lines and onychomadesis represent the most clinically significant manifestations and may serve as visible biomarkers of prior systemic insult.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">18. Clinical Phenotypes of COVID-19\u2013Associated Nail Disease<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19\u2013associated nail pathology can be organized into clinically distinct phenotypic clusters based on morphology, severity, and timing.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">18.1 Growth arrest phenotype<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This is the most common presentation and includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Beau\u2019s lines<\/li>\n\n\n\n<li>transverse nail depressions<\/li>\n\n\n\n<li>temporary slowing of nail growth<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These findings reflect transient matrix suppression and are strongly associated with systemic inflammatory burden during acute infection.\u00b9<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">18.2 Matrix failure phenotype<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">More severe disruption of nail production results in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>onychomadesis (proximal nail shedding)<\/li>\n\n\n\n<li>partial or complete nail plate detachment<\/li>\n\n\n\n<li>prolonged regrowth delay<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This phenotype is more frequently observed in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>hospitalized patients<\/li>\n\n\n\n<li>individuals with hypoxic respiratory failure<\/li>\n\n\n\n<li>patients with multisystem inflammatory involvement<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">18.3 Vascular dyschromia phenotype<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>erythronychia<\/li>\n\n\n\n<li>leukonychia<\/li>\n\n\n\n<li>distal nail bed discoloration<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These changes are believed to reflect microvascular injury and endothelial dysfunction.\u00b2<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">18.4 Brittle nail \/ dystrophic recovery phenotype<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Seen in post-acute COVID-19:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>longitudinal ridging<\/li>\n\n\n\n<li>nail fragility<\/li>\n\n\n\n<li>splitting (onychoschizia)<\/li>\n\n\n\n<li>slow normalization of plate quality<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This phenotype may persist for months after systemic recovery.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">19. Temporal Evolution and Longitudinal Outcomes<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">19.1 Acute phase (0\u20134 weeks)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">During acute infection:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>no visible nail changes<\/li>\n\n\n\n<li>systemic inflammatory and hypoxic insult occurs at matrix level<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">19.2 Early post-acute phase (4\u201312 weeks)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">First visible manifestations:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Beau\u2019s lines emerge<\/li>\n\n\n\n<li>early dyschromia appears<\/li>\n\n\n\n<li>subtle nail growth irregularities detected<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This delay reflects physiological nail growth kinetics.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">19.3 Late post-acute phase (3\u20139 months)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>full expression of transverse lines<\/li>\n\n\n\n<li>onychomadesis becomes clinically evident<\/li>\n\n\n\n<li>toenail changes lag significantly behind fingernails<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">19.4 Recovery phase (&gt;6\u201312 months)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>gradual normalization of nail growth<\/li>\n\n\n\n<li>residual ridging in severe cases<\/li>\n\n\n\n<li>persistent dystrophy in long COVID subset<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent abnormalities suggest prolonged or repeated systemic injury.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">20. Pediatric Nail Manifestations of COVID-19<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Children exhibit a distinct pattern of nail involvement.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">20.1 Higher prevalence of onychomadesis<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pediatric cases show disproportionately higher rates of nail shedding, possibly due to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>higher baseline nail growth rate<\/li>\n\n\n\n<li>heightened inflammatory responsiveness<\/li>\n\n\n\n<li>association with multisystem inflammatory syndrome in children (MIS-C)<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">20.2 Association with febrile viral syndromes<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Some pediatric cases overlap with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>hand-foot-mouth\u2013like illness patterns<\/li>\n\n\n\n<li>post-viral desquamation syndromes<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">20.3 Prognosis in children<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pediatric nail changes are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>typically self-limited<\/li>\n\n\n\n<li>fully reversible within 3\u20136 months<\/li>\n\n\n\n<li>rarely associated with chronic nail dystrophy<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">21. Toenail Versus Fingernail Differences<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A key feature of COVID-19\u2013associated nail disease is <strong>asynchronous involvement of fingernails and toenails<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">21.1 Fingernails<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>earlier manifestation (weeks)<\/li>\n\n\n\n<li>more frequently observed<\/li>\n\n\n\n<li>more sensitive to acute systemic changes<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">21.2 Toenails<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>delayed manifestation (months)<\/li>\n\n\n\n<li>more severe structural distortion when present<\/li>\n\n\n\n<li>longer recovery timeline<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This difference is attributable to slower toenail growth rates and reduced perfusion.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">22. Differential Severity Correlation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Several observational studies suggest correlation between nail pathology severity and systemic disease intensity:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>mild outpatient COVID-19 \u2192 subtle Beau\u2019s lines<\/li>\n\n\n\n<li>moderate disease \u2192 visible transverse grooves<\/li>\n\n\n\n<li>severe\/hospitalized cases \u2192 onychomadesis and multiple nail involvement<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This supports a <strong>dose\u2013response relationship between systemic inflammatory burden and nail matrix injury<\/strong>.\u00b3<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">23. Therapeutic Considerations<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">There is no direct antiviral therapy targeting nail pathology; management is supportive and restorative.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">23.1 General management principles<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>reassurance (self-limited nature in most cases)<\/li>\n\n\n\n<li>avoidance of mechanical trauma<\/li>\n\n\n\n<li>hydration optimization<\/li>\n\n\n\n<li>correction of nutritional deficiencies<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">23.2 Nutritional and metabolic support<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Evidence supports potential benefit from:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>zinc supplementation (keratinocyte proliferation support)<\/li>\n\n\n\n<li>biotin (nail plate structural integrity)<\/li>\n\n\n\n<li>protein repletion in post-illness catabolism<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">However, high-quality randomized trials are lacking.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">23.3 Management of Beau\u2019s lines<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>no direct intervention required<\/li>\n\n\n\n<li>cosmetic camouflage if desired<\/li>\n\n\n\n<li>monitoring regrowth progression<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">23.4 Management of onychomadesis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>nail protection to prevent infection<\/li>\n\n\n\n<li>hygiene maintenance<\/li>\n\n\n\n<li>antifungal prophylaxis only if secondary infection suspected<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Regrowth typically occurs within 3\u20134 months.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">23.5 Experimental and emerging approaches<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Hypothesis-driven therapies include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>anti-inflammatory modulation (targeting IL-6 axis)<\/li>\n\n\n\n<li>microvascular support agents<\/li>\n\n\n\n<li>autonomic regulation therapies for long COVID-associated dysautonomia<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These remain investigational.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">24. Long COVID and Persistent Nail Dysfunction<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A subset of patients exhibit prolonged nail abnormalities beyond 6\u201312 months.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Proposed mechanisms include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>persistent low-grade inflammation<\/li>\n\n\n\n<li>endothelial dysfunction persistence<\/li>\n\n\n\n<li>autonomic imbalance affecting peripheral circulation<\/li>\n\n\n\n<li>possible immune dysregulation affecting epithelial renewal<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This overlaps with broader post-COVID syndrome affecting skin, hair, and mucosal structures.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">25. Clinical Implications for Practice<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19\u2013associated nail findings have several important clinical implications:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">25.1 Retrospective diagnosis<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nail changes may identify prior unrecognized infection.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">25.2 Severity inference<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nail involvement may correlate with systemic disease intensity.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">25.3 Long COVID assessment<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent nail dystrophy may reflect ongoing systemic dysfunction.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">25.4 Dermatologic surveillance<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nails provide a non-invasive window into systemic recovery trajectory.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">26. Integrated Clinical Model<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19 nail pathology can be conceptualized as a <strong>time-delayed biomarker system<\/strong>:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 1 \u2014 Systemic insult<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>cytokine surge<\/li>\n\n\n\n<li>hypoxia<\/li>\n\n\n\n<li>endothelial injury<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 2 \u2014 Nail matrix arrest<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>proliferation suppression<\/li>\n\n\n\n<li>vascular compromise<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 3 \u2014 Structural manifestation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Beau\u2019s lines<\/li>\n\n\n\n<li>dyschromia<\/li>\n\n\n\n<li>onychomadesis<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 4 \u2014 Recovery or persistence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>normalization OR chronic dystrophy<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">27. Conclusion <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19 produces a spectrum of nail unit abnormalities that reflect systemic inflammatory, vascular, and hypoxic injury. These findings are delayed in onset due to the slow kinetics of nail growth but serve as reliable retrospective indicators of physiologic stress.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The nail unit should be considered:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>a biomarker of systemic infection severity<\/li>\n\n\n\n<li>a delayed recorder of inflammatory events<\/li>\n\n\n\n<li>a potential clinical adjunct in long COVID evaluation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">28. Integrated Pathophysiologic Model of COVID-19 Nail Disease<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19\u2013associated nail pathology is best understood as a <strong>multisystem convergence disorder of the nail matrix<\/strong>, resulting from synchronized disruption across inflammatory, vascular, hypoxic, and neuroendocrine domains.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">28.1 Core mechanistic axes<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">(1) Inflammatory axis<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">SARS-CoV-2 infection induces systemic elevation of IL-6, TNF-\u03b1, and IL-1\u03b2, which suppress keratinocyte proliferation and disrupt epithelial renewal.\u00b9\u2013\u00b3<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">(2) Vascular axis<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Endothelial injury and microthrombosis impair perfusion of the highly terminal nail matrix circulation.\u2074\u2013\u2076<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">(3) Hypoxic axis<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Systemic hypoxemia and mitochondrial dysfunction inhibit ATP-dependent keratinocyte division.\u2077\u2013\u2078<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">(4) Neuroendocrine axis<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Autonomic dysregulation and cortisol-mediated stress responses further suppress nail growth kinetics.\u2079<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">(5) Immune remodeling axis<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Post-viral immune dysregulation may sustain low-grade inflammatory signaling in epithelial structures, contributing to long COVID nail dystrophy.\u00b9\u2070<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">29. Unified Disease Model<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19 nail pathology follows a predictable temporal cascade:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 1 \u2014 Acute systemic insult (0\u20133 weeks)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>cytokine surge<\/li>\n\n\n\n<li>endothelial activation<\/li>\n\n\n\n<li>hypoxia episodes<\/li>\n\n\n\n<li>metabolic stress<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 2 \u2014 Nail matrix arrest (2\u20138 weeks)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>keratinocyte proliferation suppression<\/li>\n\n\n\n<li>vascular perfusion instability<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 3 \u2014 Structural expression (4\u201324 weeks)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Beau\u2019s lines<\/li>\n\n\n\n<li>dyschromia<\/li>\n\n\n\n<li>onychomadesis<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Phase 4 \u2014 Recovery or persistence (3\u201312+ months)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>regrowth normalization OR chronic dystrophy in long COVID<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">30. Table 1 \u2014 COVID-19\u2013Associated Nail Findings<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Nail Finding<\/th><th>Mechanism<\/th><th>Timing<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td>Beau\u2019s lines<\/td><td>growth arrest<\/td><td>4\u201312 weeks<\/td><td>systemic stress marker<\/td><\/tr><tr><td>Onychomadesis<\/td><td>matrix failure<\/td><td>6\u201316 weeks<\/td><td>severe systemic insult<\/td><\/tr><tr><td>Erythronychia<\/td><td>vascular injury<\/td><td>variable<\/td><td>endothelial dysfunction<\/td><\/tr><tr><td>Leukonychia<\/td><td>keratin disruption<\/td><td>weeks\u2013months<\/td><td>metabolic stress<\/td><\/tr><tr><td>Brittle nails<\/td><td>chronic remodeling<\/td><td>months<\/td><td>long COVID association<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">31. Table 2 \u2014 Mechanistic Pathways<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Pathway<\/th><th>Key Mediators<\/th><th>Effect<\/th><\/tr><\/thead><tbody><tr><td>Inflammatory<\/td><td>IL-6, TNF-\u03b1, IL-1\u03b2<\/td><td>keratinocyte suppression<\/td><\/tr><tr><td>Vascular<\/td><td>endothelial injury, microthrombi<\/td><td>ischemia<\/td><\/tr><tr><td>Hypoxic<\/td><td>HIF-1\u03b1 activation<\/td><td>metabolic arrest<\/td><\/tr><tr><td>Neuroendocrine<\/td><td>cortisol, autonomic imbalance<\/td><td>growth inhibition<\/td><\/tr><tr><td>Immune<\/td><td>persistent cytokine signaling<\/td><td>chronic dystrophy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">32. Figure Legends <\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Figure 1 \u2014 SARS-CoV-2\u2013induced nail matrix injury pathway<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Diagram illustrating inflammatory cytokine cascade (IL-6, TNF-\u03b1), endothelial injury, and hypoxia converging on nail matrix keratinocyte arrest.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Figure 2 \u2014 Temporal evolution of COVID-19 nail findings<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Timeline showing:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>acute infection phase<\/li>\n\n\n\n<li>delayed emergence of Beau\u2019s lines<\/li>\n\n\n\n<li>later onychomadesis and regrowth<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Figure 3 \u2014 Nail growth as biological recorder of systemic disease<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Illustration mapping systemic inflammatory event \u2192 nail matrix arrest \u2192 visible transverse band formation months later.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">33. Clinical Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">33.1 Diagnostic value<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nail changes provide a <strong>retrospective biomarker of systemic inflammatory burden<\/strong>, particularly useful in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>unrecognized COVID-19 infection<\/li>\n\n\n\n<li>long COVID evaluation<\/li>\n\n\n\n<li>post-hospitalization follow-up<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">33.2 Severity correlation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Extent of nail involvement correlates with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>disease severity<\/li>\n\n\n\n<li>duration of hypoxia<\/li>\n\n\n\n<li>systemic inflammatory load<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">33.3 Long COVID relevance<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent nail dystrophy may reflect:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ongoing endothelial dysfunction<\/li>\n\n\n\n<li>chronic immune activation<\/li>\n\n\n\n<li>autonomic imbalance<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">34. Therapeutic Considerations<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">No targeted pharmacologic therapy exists for COVID-19\u2013induced nail pathology; management remains supportive:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">34.1 General measures<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>reassurance (self-limited nature in most cases)<\/li>\n\n\n\n<li>avoidance of mechanical trauma<\/li>\n\n\n\n<li>hydration and nail protection<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">34.2 Nutritional support<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>zinc supplementation (keratinocyte support)<\/li>\n\n\n\n<li>biotin (structural keratin integrity)<\/li>\n\n\n\n<li>protein repletion post-catabolic illness<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">34.3 Symptomatic management<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>emollients for brittle nails<\/li>\n\n\n\n<li>management of secondary infection if present<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">34.4 Investigational approaches<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>microvascular support therapies<\/li>\n\n\n\n<li>anti-inflammatory modulation targeting IL-6 axis<\/li>\n\n\n\n<li>autonomic regulation therapies in long COVID<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">35. Limitations of Current Evidence<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>predominance of case reports and small observational cohorts<\/li>\n\n\n\n<li>limited histopathologic confirmation of nail matrix injury<\/li>\n\n\n\n<li>lack of longitudinal population-level nail imaging studies<\/li>\n\n\n\n<li>underreporting of toenail pathology<\/li>\n\n\n\n<li>confounding by systemic illness and medication exposure<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">36. Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19 produces a distinctive and temporally delayed spectrum of nail unit abnormalities resulting from the convergence of inflammatory, vascular, hypoxic, and neuroendocrine injury pathways. The nail unit functions as a <strong>biological archive of systemic disease severity<\/strong>, encoding prior physiologic stress events in a slow-growing keratinized structure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Recognition of nail involvement in COVID-19 expands the disease paradigm beyond acute respiratory illness to a <strong>multisystem endothelial-immune-epithelial disorder<\/strong> with lasting integumentary consequences.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Footnotes <\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Del Valle DM et al. An inflammatory cytokine signature predicts COVID-19 severity. <em>Nat Med.<\/em> 2020.<\/li>\n\n\n\n<li>Feghali-Bostwick CA et al. IL-6 signaling and epithelial proliferation regulation. <em>J Immunol.<\/em> 2008.<\/li>\n\n\n\n<li>Balkwill F. TNF-\u03b1 in inflammation and cancer. <em>Nat Rev Cancer.<\/em> 2009.<\/li>\n\n\n\n<li>Varga Z et al. Endothelial cell infection and endotheliitis in COVID-19. <em>Lancet.<\/em> 2020;395:1417\u20131418.<\/li>\n\n\n\n<li>Ackermann M et al. Pulmonary vascular endothelialitis in COVID-19. <em>N Engl J Med.<\/em> 2020;383:120\u2013128.<\/li>\n\n\n\n<li>Magro C et al. Complement-associated microvascular injury in COVID-19. <em>Transl Res.<\/em> 2020.<\/li>\n\n\n\n<li>Tobin MJ. Bending the curve: silent hypoxia in COVID-19. <em>Am J Respir Crit Care Med.<\/em> 2020.<\/li>\n\n\n\n<li>Semenza GL. Hypoxia-inducible factors in physiology and medicine. <em>Cell.<\/em> 2012.<\/li>\n\n\n\n<li>Freeman EE et al. COVID-19 cutaneous manifestations registry data. <em>Br J Dermatol.<\/em> 2020.<\/li>\n\n\n\n<li>Piccolo V et al. Nail changes after COVID-19 infection. <em>J Eur Acad Dermatol Venereol.<\/em> 2021.<\/li>\n\n\n\n<li>Ghosh A et al. Systemic inflammatory effects of SARS-CoV-2. <em>Clin Immunol.<\/em> 2021.<\/li>\n\n\n\n<li>Gupta A et al. Dermatologic sequelae of COVID-19. <em>J Am Acad Dermatol.<\/em> 2021.<\/li>\n\n\n\n<li>Wollina U. COVID-19 and skin manifestations. <em>Clin Dermatol.<\/em> 2020.<\/li>\n\n\n\n<li>Fabbrocini G et al. Nail disorders in systemic disease. <em>Dermatol Ther.<\/em> 2019.<\/li>\n\n\n\n<li>Recalcati S. Cutaneous manifestations in COVID-19. <em>J Eur Acad Dermatol Venereol.<\/em> 2020.<\/li>\n\n\n\n<li>Tang N et al. Coagulation abnormalities in COVID-19. <em>J Thromb Haemost.<\/em> 2020.<\/li>\n\n\n\n<li>Tehrani H et al. Autonomic dysfunction in post-COVID syndrome. <em>Neurology.<\/em> 2021.<\/li>\n\n\n\n<li>Gupta M et al. Nail unit pathology in systemic inflammatory disease. <em>Int J Dermatol.<\/em> 2018.<\/li>\n\n\n\n<li>Gupta M et al. Cutaneous and nail manifestations in COVID-19. <em>J Am Acad Dermatol.<\/em> 2021.<\/li>\n\n\n\n<li>Piccolo V et al. Nail findings after SARS-CoV-2 infection. <em>J Eur Acad Dermatol Venereol.<\/em> 2021.<\/li>\n\n\n\n<li>Fern\u00e1ndez-Nieto D et al. COVID-19 skin and nail manifestations registry. <em>Br J Dermatol.<\/em> 2020.<\/li>\n\n\n\n<li>Recalcati S. Cutaneous manifestations in COVID-19. <em>J Eur Acad Dermatol Venereol.<\/em> 2020.<\/li>\n\n\n\n<li>Wollina U. Dermatologic aspects of COVID-19. <em>Clin Dermatol.<\/em> 2020.<\/li>\n\n\n\n<li>Daneshgaran G et al. Nail changes in systemic viral infections. <em>Dermatol Ther.<\/em> 2020.<\/li>\n\n\n\n<li>Elmas \u00d6F et al. Post-COVID nail disorders. <em>Dermatol Ther.<\/em> 2021.<\/li>\n\n\n\n<li>Battista T et al. Beau\u2019s lines in systemic disease. <em>Int J Dermatol.<\/em> 2019.<\/li>\n\n\n\n<li>Wu Z et al. Clinical features of COVID-19 severity spectrum. <em>Lancet.<\/em> 2020.<\/li>\n\n\n\n<li>Huang C et al. Clinical features of COVID-19 patients. <em>Lancet.<\/em> 2020.<\/li>\n\n\n\n<li>Tang N et al. Coagulation dysfunction in COVID-19. <em>J Thromb Haemost.<\/em> 2020.<\/li>\n\n\n\n<li>Ackermann M et al. Pulmonary vascular injury in COVID-19. <em>N Engl J Med.<\/em> 2020.<\/li>\n\n\n\n<li>Varga Z et al. Endothelial cell infection in COVID-19. <em>Lancet.<\/em> 2020.<\/li>\n\n\n\n<li>Tobin MJ. Hypoxia in COVID-19. <em>Am J Respir Crit Care Med.<\/em> 2020.<\/li>\n\n\n\n<li>Semenza GL. Hypoxia-inducible factors. <em>Cell.<\/em> 2012.<\/li>\n\n\n\n<li>Freeman EE et al. COVID-19 dermatology registry. <em>Br J Dermatol.<\/em> 2020.<\/li>\n\n\n\n<li>Fabbrocini G et al. Nail disorders in systemic disease. <em>Dermatol Ther.<\/em> 2019.<\/li>\n\n\n\n<li>Wollina U. Nail pathology review. <em>Clin Dermatol.<\/em> 2020.<\/li>\n\n\n\n<li>Gupta AK et al. Nail unit diseases overview. <em>Int J Dermatol.<\/em> 2018.<\/li>\n\n\n\n<li>Del Valle DM et al. Nat Med. 2020.<\/li>\n\n\n\n<li>Huang C et al. Lancet. 2020.<\/li>\n\n\n\n<li>Chen G et al. J Clin Invest. 2020.<\/li>\n\n\n\n<li>Varga Z et al. Lancet. 2020;395:1417\u20131418.<\/li>\n\n\n\n<li>Ackermann M et al. N Engl J Med. 2020;383:120\u2013128.<\/li>\n\n\n\n<li>Magro C et al. Transl Res. 2020.<\/li>\n\n\n\n<li>Tobin MJ. Am J Respir Crit Care Med. 2020.<\/li>\n\n\n\n<li>Semenza GL. Cell. 2012.<\/li>\n\n\n\n<li>Freeman EE et al. Br J Dermatol. 2020.<\/li>\n\n\n\n<li>Nalbandian A et al. Nat Med. 2021.<\/li>\n\n\n\n<li>Gupta M et al. J Am Acad Dermatol. 2021.<\/li>\n\n\n\n<li>Piccolo V et al. J Eur Acad Dermatol Venereol. 2021.<\/li>\n\n\n\n<li>Fern\u00e1ndez-Nieto D et al. Br J Dermatol. 2020.<\/li>\n\n\n\n<li>Wollina U. Clin Dermatol. 2020.<\/li>\n\n\n\n<li>Recalcati S. J Eur Acad Dermatol Venereol. 2020.<\/li>\n\n\n\n<li>Daneshgaran G et al. Dermatol Ther. 2020.<\/li>\n\n\n\n<li>Elmas \u00d6F et al. Dermatol Ther. 2021.<\/li>\n\n\n\n<li>Battista T et al. Int J Dermatol. 2019.<\/li>\n\n\n\n<li>Fabbrocini G et al. Dermatol Ther. 2019.<\/li>\n\n\n\n<li>Gupta AK et al. Int J Dermatol. 2018.<\/li>\n\n\n\n<li>Tang N et al. J Thromb Haemost. 2020.<\/li>\n\n\n\n<li>Wang D et al. JAMA. 2020.<\/li>\n\n\n\n<li>Zhou F et al. Lancet. 2020.<\/li>\n\n\n\n<li>Wu Z et al. Lancet. 2020.<\/li>\n\n\n\n<li>Semmler BE et al. Clin Immunol. 2021.<\/li>\n\n\n\n<li>Mehta P et al. Lancet. 2020.<\/li>\n\n\n\n<li>Sinha P et al. Science. 2020.<\/li>\n\n\n\n<li>Robba C et al. Crit Care. 2020.<\/li>\n\n\n\n<li>Gattinoni L et al. Intensive Care Med. 2020.<\/li>\n\n\n\n<li>Guan WJ et al. N Engl J Med. 2020.<\/li>\n\n\n\n<li>Huang R et al. Nat Rev Microbiol. 2020.<\/li>\n\n\n\n<li>Sato Y et al. J Dermatol Sci. 2021.<\/li>\n\n\n\n<li>Wollina U et al. J Clin Med. 2021.<\/li>\n\n\n\n<li>Khanna D et al. Arthritis Rheumatol. 2021.<\/li>\n\n\n\n<li>Lopez-Leon S et al. Sci Rep. 2021.<\/li>\n\n\n\n<li>Yong SJ. Nat Rev Neurol. 2021.<\/li>\n\n\n\n<li>Davis HE et al. eClinicalMedicine. 2021.<\/li>\n\n\n\n<li>Nalbandian A et al. Nat Med. 2021.<\/li>\n\n\n\n<li>Sudre CH et al. Nat Med. 2021.<\/li>\n\n\n\n<li>Taquet M et al. Lancet Psychiatry. 2021.<\/li>\n\n\n\n<li>Bullock K et al. J Infect. 2020.<\/li>\n\n\n\n<li>Crook H et al. BMJ. 2021.<\/li>\n\n\n\n<li>Oved K et al. Clin Infect Dis. 2020.<\/li>\n\n\n\n<li>To KK et al. Clin Infect Dis. 2020.<\/li>\n\n\n\n<li>Wyllie AL et al. N Engl J Med. 2020.<\/li>\n\n\n\n<li>Azzi L et al. J Infect. 2020.<\/li>\n\n\n\n<li>Becker RC. J Thromb Thrombolysis. 2020.<\/li>\n\n\n\n<li>Guo T et al. J Thromb Haemost. 2020.<\/li>\n\n\n\n<li>Ortega JT et al. Virus Res. 2020.<\/li>\n\n\n\n<li>Pascual M et al. J Oral Pathol Med. 2020.<\/li>\n\n\n\n<li>Brandtzaeg P. Immunol Rev. 2013.<\/li>\n\n\n\n<li>Te Velde AA et al. Nat Rev Immunol. 20<\/li>\n\n\n\n<li>Del Valle DM et al. Nat Med. 2020.<\/li>\n\n\n\n<li>Huang C et al. Lancet. 2020.<\/li>\n\n\n\n<li>Chen G et al. J Clin Invest. 2020.<\/li>\n\n\n\n<li>Varga Z et al. Lancet. 2020;395:1417\u20131418.<\/li>\n\n\n\n<li>Ackermann M et al. N Engl J Med. 2020;383:120\u2013128.<\/li>\n\n\n\n<li>Magro C et al. Transl Res. 2020.<\/li>\n\n\n\n<li>Tobin MJ. Am J Respir Crit Care Med. 2020.<\/li>\n\n\n\n<li>Semenza GL. Cell. 2012.<\/li>\n\n\n\n<li>Freeman EE et al. Br J Dermatol. 2020.<\/li>\n\n\n\n<li>Nalbandian A et al. Nat Med. 2021.<\/li>\n\n\n\n<li>Gupta M et al. J Am Acad Dermatol. 2021.<\/li>\n\n\n\n<li>Piccolo V et al. J Eur Acad Dermatol Venereol. 2021.<\/li>\n\n\n\n<li>Fern\u00e1ndez-Nieto D et al. Br J Dermatol. 2020.<\/li>\n\n\n\n<li>Wollina U. Clin Dermatol. 2020.<\/li>\n\n\n\n<li>Recalcati S. J Eur Acad Dermatol Venereol. 2020.<\/li>\n\n\n\n<li>Daneshgaran G et al. Dermatol Ther. 2020.<\/li>\n\n\n\n<li>Elmas \u00d6F et al. Dermatol Ther. 2021.<\/li>\n\n\n\n<li>Battista T et al. Int J Dermatol. 2019.<\/li>\n\n\n\n<li>Fabbrocini G et al. Dermatol Ther. 2019.<\/li>\n\n\n\n<li>Gupta AK et al. Int J Dermatol. 2018.<\/li>\n\n\n\n<li>Tang N et al. J Thromb Haemost. 2020.<\/li>\n\n\n\n<li>Wang D et al. JAMA. 2020.<\/li>\n\n\n\n<li>Zhou F et al. Lancet. 2020.<\/li>\n\n\n\n<li>Wu Z et al. Lancet. 2020.<\/li>\n\n\n\n<li>Semmler BE et al. Clin Immunol. 2021.<\/li>\n\n\n\n<li>Mehta P et al. Lancet. 2020.<\/li>\n\n\n\n<li>Sinha P et al. Science. 2020.<\/li>\n\n\n\n<li>Robba C et al. Crit Care. 2020.<\/li>\n\n\n\n<li>Gattinoni L et al. Intensive Care Med. 2020.<\/li>\n\n\n\n<li>Guan WJ et al. N Engl J Med. 2020.<\/li>\n\n\n\n<li>Huang R et al. Nat Rev Microbiol. 2020.<\/li>\n\n\n\n<li>Sato Y et al. J Dermatol Sci. 2021.<\/li>\n\n\n\n<li>Wollina U et al. J Clin Med. 2021.<\/li>\n\n\n\n<li>Khanna D et al. Arthritis Rheumatol. 2021.<\/li>\n\n\n\n<li>Lopez-Leon S et al. Sci Rep. 2021.<\/li>\n\n\n\n<li>Yong SJ. Nat Rev Neurol. 2021.<\/li>\n\n\n\n<li>Davis HE et al. eClinicalMedicine. 2021.<\/li>\n\n\n\n<li>Nalbandian A et al. Nat Med. 2021.<\/li>\n\n\n\n<li>Sudre CH et al. Nat Med. 2021.<\/li>\n\n\n\n<li>Taquet M et al. Lancet Psychiatry. 2021.<\/li>\n\n\n\n<li>Bullock K et al. J Infect. 2020.<\/li>\n\n\n\n<li>Crook H et al. BMJ. 2021.<\/li>\n\n\n\n<li>Oved K et al. Clin Infect Dis. 2020.<\/li>\n\n\n\n<li>To KK et al. Clin Infect Dis. 2020.<\/li>\n\n\n\n<li>Wyllie AL et al. N Engl J Med. 2020.<\/li>\n\n\n\n<li>Azzi L et al. J Infect. 2020.<\/li>\n\n\n\n<li>Becker RC. J Thromb Thrombolysis. 2020.<\/li>\n\n\n\n<li>Guo T et al. J Thromb Haemost. 2020.<\/li>\n\n\n\n<li>Ortega JT et al. Virus Res. 2020.<\/li>\n\n\n\n<li>Pascual M et al. J Oral Pathol Med. 2020.<\/li>\n\n\n\n<li>Brandtzaeg P. Immunol Rev. 2013.<\/li>\n\n\n\n<li>Te Velde AA et al. Nat Rev Immunol. 20<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Abstract COVID-19 is a multisystem infectious disease caused by SARS-CoV-2 with well-documented respiratory, cardiovascular, neurologic, and dermatologic manifestations. Increasing evidence indicates that the nail unit represents a delayed and visually [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1145,176,1144,585],"tags":[],"class_list":["post-14870","post","type-post","status-publish","format-standard","hentry","category-finger-nail","category-fingers","category-toe-nail","category-toes"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14870"}],"version-history":[{"count":8,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14870\/revisions"}],"predecessor-version":[{"id":14878,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14870\/revisions\/14878"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}